Literature DB >> 34182945

Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.

Jianchao Gao1, Sisi Wang2, Zhisheng Zhang1, Jun Li3.   

Abstract

BACKGROUND: BRE-AS1 is a recently identified tumor suppressor in non-small cell lung cancer. It role in other human diseases remains elusive.
METHODS: Differential expression of BRE-AS1 in with triple-negative breast cancer (TNBC) patients (n = 74, patient group) and healthy volunteers (n = 58, control group) was studied with RT-qPCR. The direct interaction between BRE-AS1 and premature microRNA-21 (miR-21) was assessed by RNA pull-down assay. The interactions among BRE-AS1, miR-21 and PTEN were evaluated by overexpression assays. CCK-8 assay and Transwell assay were used to evaluate cell behaviors.
RESULTS: BRE-AS1 was downregulated in TNBC, while miR-21 was highly expressed in TNBC. Low expression levels of lncRNA BRE-AS1 and high expression levels of miR-21 were significantly correlated with unfavorable survival outcomes. BRE-AS1 and miRNA-21 were inversely correlated across TNBC samples, not control samples. BRE-AS1 decreased miR-21 expression and increased PTEN expression while miR-21showed no role in BRE-AS1 expression. RNA pull-down assay illustrated that BRE-AS1 may sponge premature miR-21 to suppress it maturation. Overexpression of BRE-AS1 decreased cell behaviors, while overexpression of miR-21 promoted cell behaviors. MiR-21 suppressed the role of BRE-AS1 in cancer cell behaviors.
CONCLUSION: Therefore, BRE-AS1 may inhibit TNBC by downregulating miR-21.

Entities:  

Keywords:  Survival; Triple-negative breast cancer; lncRNA BRE-AS1; miR-21

Year:  2021        PMID: 34182945     DOI: 10.1186/s12885-021-08294-6

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  15 in total

Review 1.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

Review 2.  Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis.

Authors:  Yang Wang; Xujie Gao; Feng Wei; Xinwei Zhang; Jinpu Yu; Hua Zhao; Qian Sun; Fan Yan; Cihui Yan; Hui Li; Xiubao Ren
Journal:  Gene       Date:  2013-09-26       Impact factor: 3.688

3.  miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN.

Authors:  Hong Fang; Jiping Xie; Min Zhang; Ziwei Zhao; Yi Wan; Yongqiang Yao
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 4.  The Role of miR-21 in Cancer.

Authors:  Susan R Pfeffer; Chuan He Yang; Lawrence M Pfeffer
Journal:  Drug Dev Res       Date:  2015-06-16       Impact factor: 4.360

5.  The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.

Authors:  Ryan Charles Pink; Priya Samuel; Davide Massa; Daniel Paul Caley; Susan Ann Brooks; David Raul Francisco Carter
Journal:  Gynecol Oncol       Date:  2015-01-08       Impact factor: 5.482

Review 6.  Overview of resistance to systemic therapy in patients with breast cancer.

Authors:  Ana Maria Gonzalez-Angulo; Flavia Morales-Vasquez; Gabriel N Hortobagyi
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  Long non-coding RNA BRE-AS1 represses non-small cell lung cancer cell growth and survival via up-regulating NR4A3.

Authors:  Meichun Zhang; Jing Wu; Weinong Zhong; Ziwen Zhao; Zhaohui Liu
Journal:  Arch Biochem Biophys       Date:  2018-09-15       Impact factor: 4.013

8.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Authors:  Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

Review 9.  The hallmarks of cancer: a long non-coding RNA point of view.

Authors:  Tony Gutschner; Sven Diederichs
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

10.  Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Authors:  Shaokun Shu; Charles Y Lin; Housheng Hansen He; Robert M Witwicki; Doris P Tabassum; Justin M Roberts; Michalina Janiszewska; Sung Jin Huh; Yi Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G Stover; Muhammad B Ekram; Jonathan Brown; Clive D'Santos; Ian E Krop; Deborah Dillon; Michael McKeown; Christopher Ott; Jun Qi; Min Ni; Prakash K Rao; Melissa Duarte; Shwu-Yuan Wu; Cheng-Ming Chiang; Lars Anders; Richard A Young; Eric Winer; Antony Letai; William T Barry; Jason S Carroll; Henry Long; Myles Brown; X Shirley Liu; Clifford A Meyer; James E Bradner; Kornelia Polyak
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more
  1 in total

Review 1.  Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.

Authors:  Tomasz Powrózek; Michael Ochieng Otieno
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.